Table 1 Baseline values and 6-month follow-up modifications (DOR1: on doravirine switched from rilpivirine-based regimens; DOR2: on doravirine, switching from other NNRTI-containing regimens, DOR3: on doravirine, switching from INSTI-containing regimens)
Variable | DOR1 n = 35 | DOR2 n = 32 | DOR3 n = 40 | P* |
|---|---|---|---|---|
Current regimen, n (%) 3TC/TDF/DOR Dual with INSTI FTC/TAF/DOR | 31 (88.6%) 3 (8.6%) 1 (2.9%) | 17 (53.1%) 7 (21.9%) 8 (25.0%) | 22 (55.0%) 12 (30.0%) 6 (15.0%) | 0.006 |
TAF in the previous regimen, n (%) | 5 (14.3%) | 6 (18.8%) | 26 (65.0%) | < 0.0001 |
Blood lipids | ||||
Total cholesterol, mg/dL | ||||
Baseline, mean ± SD | 181 ± 40 | 203 ± 44 | 199 ± 46 | 0.079 |
T1-T0, mean (95% CI) | -6 (-18, +6) | -15 (-26, -5) | -23 (-32, -13) | 0.053 |
HDL-cholesterol, mg/dL | ||||
Baseline, mean ± SD | 46 ± 13 | 55 ± 14 | 49 ± 16 | 0.020 |
T1-T0, mean (95% CI) | 3 (-1, +8) | -2 (-6, +2) | -0 (-3, +3) | 0.059 |
Total cholesterol /HDL-cholesterol | ||||
Baseline, median (IQR) | 4.0 (3.6–4.7) | 3.6 (3.1–4.5) | 4.1 (3.4–4.9) | 0.339 |
T1-T0, mean (95% CI) | -0.23 (-0.61,+ 0.14) | -0.19 (-0.54, +0.16) | -0.45 (-0.75, -0.15) | 0.435 |
LDL-cholesterol, mg/dL | ||||
Baseline, mean ± SD | 110 ± 34 | 119 ± 37 | 120 ± 42 | 0.530 |
T1-T0, mean (95% CI) | -8 (-18, +3) | -12 (-22, -3) | -22 (-31, -14) | 0.055 |
Triglycerides, mg/dL | ||||
Baseline, median (IQR) | 121 (75–145) | 107 (89–152) | 120 (99–200) | 0.156 |
T1-T0, mean (95% CI) | -9 (-38, +18) | -19 (-43, +6) | -8 (-30, +14) | 0.791 |
Liver enzymes | ||||
ALT ≤ 40 UI/L at T0, n (%) | 29 (82.9%) | 27 (84.4%) | 30 (75.0%) | 0.550 |
Baseline, median (IQR) | 21 (19–27) | 19 (14–26) | 19 (15–26) | 0.586 |
T1-T0, mean (95% CI) | -2 (-7, +2) | 1 (-3, +6) | 2 (-1, +6) | 0.211 |
ALT > 40 UI/L at T0, n (%) | 6 (17.1%) | 5 (15.6%) | 10 (25.0%) | 0.550 |
Baseline, median (IQR) | 50 (45–63) | 49 (42–74) | 80 (51–91) | 0.260 |
T1-T0, mean (95% CI) | -18 (-44, +7) | 10 (-16, +37) | -26 (-42, -9) | 0.084 |